Sign inCreate account

Report workspace tools

NCT04554940ACTIVE_NOT_RECRUITINGanonymous

A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression Surgery

Sponsor

Source record

BioMarin Pharmaceutical

Phase

Source record

PHASE2

Modality

AI-normalized

protein therapy

Target

AI-normalized

vosoritide

Indication / condition

AI-normalized

Achondroplasia

Intervention

Source record

vosoritide

Source & freshness

Source record

NCT ID

NCT04554940

Original source

ClinicalTrials.gov

Source last updated

Mar 13, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04554940

Title

A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression Surgery

Sponsor

BioMarin Pharmaceutical

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE2

Condition raw

Achondroplasia

Condition normalized

Achondroplasia

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

vosoritide

Target normalized

vosoritide

Interventions

vosoritide

Public preview

Source record

Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression Surgery

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04554940

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE2

Sponsor

BioMarin Pharmaceutical

Executive brief

Investment-Ready Snapshot

Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 13, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04554940

Indication

Achondroplasia

Modality

protein therapy

Target

vosoritide

Intervention

vosoritide

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.